GlassScriptPhysician profile
James L Gilbert
NPI 1801806765
$4,008.88
in general payments reported to CMS, 2019-2025
28 companies · $660 in 2025
The $660 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $229 · 2021: $315 · 2022: $339 · 2023: $985 · 2024: $864 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $661.34 | 2019-2024 | Xarelto |
| Pfizer INC. | $555.71 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.19 | 2019-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $406.57 | 2023-2025 | Qelbree, Qelbree |
| Gilead Sciences, INC. | $242.74 | 2023-2024 | Veklury |
| Ucb, INC. | $237.52 | 2022-2024 | Briviact |
| Novartis Pharmaceuticals Corporation | $232.39 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $211.11 | 2024-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.46 | 2019-2024 | Jardiance, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $133.00 | 2019-2025 | |
| Abbvie INC. | $117.46 | 2024-2025 | |
| Novo Nordisk INC | $108.59 | 2020-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $63.19 | 2019-2025 | Ultomiris |
| Melinta Therapeutics, LLC | $54.80 | 2019 | |
| Xeris Pharmaceuticals, INC. | $48.13 | 2023-2024 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $43.47 | 2024 | |
| Merck Sharp & Dohme LLC | $30.94 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Ultragenyx Pharmaceutical INC. | $29.91 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $28.21 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.20 | 2023 | Lifevest |
| Kyowa Kirin, INC. | $21.00 | 2024 | Crysvita |
| Inari Medical, INC. | $20.46 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Otsuka America Pharmaceutical, INC. | $19.96 | 2019 | |
| Cvrx, INC. | $19.55 | 2025 | Barostim Neo System |
| Nabriva Therapeutics, Plc | $19.35 | 2020 | |
| Celgene Corporation | $18.04 | 2022 | |
| Sanofi Pasteur INC. | $17.18 | 2019 | |
| Cmp Pharma, INC. | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.